반응식
[F:1][C:2]([F:19])([F:18])[C:3]1[CH:8]=[CH:7][C:6]([S:9]([N:12]2[CH2:17][CH2:16][NH:15][CH2:14][CH2:13]2)(=[O:11])=[O:10])=[CH:5][CH:4]=1.[Br:20][C:21]1[CH:26]=[CH:25][N:24]=[C:23]([C:27](O)=[O:28])[CH:22]=1.C1C=CC2N(O)N=NC=2C=1.O.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C>CN(C=O)C>[Br:20][C:21]1[CH:26]=[CH:25][N:24]=[C:23]([C:27]([N:15]2[CH2:16][CH2:17][N:12]([S:9]([C:6]3[CH:5]=[CH:4][C:3]([C:2]([F:1])([F:18])[F:19])=[CH:8][CH:7]=3)(=[O:10])=[O:11])[CH2:13][CH2:14]2)=[O:28])[CH:22]=1참가 물질
반응물 6
생성물 1
시약·촉매·용매 1
실험 절차
To a solution of 1-{[4-(trifluoromethyl)phenyl]sulfonyl}piperazine (Description 1) (200 mg, 0.680 mmol) in DMF (10 ml) was added 4-bromo-2-pyridinecarboxylic acid (137 mg, 0.680 mmol), HOBT.H2O (104 mg, 0.680 mmol), HBTU (258 mg, 0.680 mmol) and DIPEA (0.356 ml, 2.039 mmol) and the reaction mixture was stirred at room temperature for 2.5 hours. The DMF was evaporated under vacuo then 10 ml of DCM were added and washed with 2M aq. HCl solution (10 ml) saturated aq. NaHCO3 solution (10 ml) and brine (10 ml), dried on a phase separation cartridge and evaporated in vacuo. The crude material was purified by silica chromatography using a gradient isohexane/EtOAc [100/0] to [50/50] then to [0/100]). The desired fractions were then collected and concentrated to dryness to give the title compound (171 mg).
후처리
- customThe DMF was evaporated under vacuo
- addition10 ml of DCM were added
- washwashed with 2M aq. HCl solution (10 ml) saturated aq. NaHCO3 solution (10 ml) and brine (10 ml)
- customdried on a phase separation cartridge
- customevaporated in vacuo
- customThe crude material was purified by silica chromatography
- customThe desired fractions were then collected
- concentrationconcentrated to dryness
출처 및 근거
- ORD 기록
- ord-1c93b49c023848188c711506999d0e7e
- 출처 데이터셋
- uspto-grants-2013_09
- 특허 번호
- US08530478B2
연결된 노트
불러오는 중…